Abstract 473P
Background
The combination of endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDKi) for ER+HER2neg metastatic breast cancer has been associated with 13% of drug-induced liver injury (DILI). In a previous work (Vega et al, ESMO Breast 2023), we identified 26 cases of DILI (5.5%), defined as AST/ALT elevation ≥G2, among 472 patients (pts) treated. Here, we present a case-control study to evaluate the clinical factors associated with DILI.
Methods
The case-control study includes i) 89 pts without DILI randomly selected and retrospectively analyzed (control group) and ii) 26 cases with DILI previously reported. 15 potential predictive factors were evaluated either individually or in combination. Baseline liver steatosis was based on computed tomography reports. To study the association with DILI, odds ratios (ORs) were calculated using logistic regression.
Results
The main characteristics of the 115 pts are shown in the table. In the univariate analysis, no baseline risk factor alone was statistically associated with DILI, steatosis and AST/ALT baseline elevation had the best results (p<0.15). However, the combination of steatosis and pre-menopause status (n=9, 7.8%) significantly increased the risk to 66.7% vs 19% (20/105) (OR=8.6, 95% CI 2.1-43.6; p=0.004). No other variables, including cardiovascular risk factors, ET partner or liver metastasis predicted DILI development.
Table: 473P
Baseline characteristics of cases and control
Cases n=26 | Controls n=89 | |
Palbociclib | 8 | 32 |
Abemaciclib | 9 | 29 |
Ribociclib | 9 | 28 |
Age (median) | 61 | 60 |
Overweight | 33% | 36% |
Obesity | 26% | 28% |
Pre-Menopause | 54% | 35% |
Hypertension | 27% | 27% |
Diabetes mellitus | 4% | 11% |
Dyslipidemia | 31% | 29% |
Aromatase inhibitor | 65% | 57% |
Fulvestrant | 35% | 43% |
Liver metastasis | 27% | 30% |
Steatosis | 31% | 15% |
Baseline ALT or AST >35 IU/mL | 36% | 17% |
Conclusions
In our case-control series, the combination of premenopausal status and steatosis was the strongest predictor for CDKi-related DILI. Our findings suggest that metabolic changes due to ovarian factor suppression cooperate with CDKi to induce DILI in pts with underlying steatosis. A prospective study is needed to validate these findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
VHIO.
Funding
Has not received any funding.
Disclosure
C. Saura Manich: Financial Interests, Personal, Advisory Board: AstraZeneca, Boehringer Ingelheim, Bristol Meyers Squibb, Daiichi Sankyo, Eisai, Exact Sciences, Exeter Pharma, F. Hoffmann - La Roche Ltd, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Philips, Piere Fabre, PintPharma, Puma, Roche Farma, Sanofi-Aventis, SeaGen, Zymeworks, Genentech, Innoup, Millenium, Pharmalex Spain SLU; Financial Interests, Personal, Other, SC: Byondis B.V., Glaxo, Macrogenics, Menarini, Merus, Synthon Biopharpaceuticals; Financial Interests, Institutional, Research Grant: AstraZeneca, Bayer Pharma, Boehringer Ingelheim, Bristol Myers Squibb (BMS), Cytomx Therapeutics, Daiichi Sankyo, Eli Lilly and Company, F. Hoffmann-La RocheLtd, Genentech, GSK, Immunomedics, Innoup Farma, Macrogenics, Menarini Ricerche, Merus, Novartis, Pfizer, Puma, Roche, Sanofi-Aventis, Seattle Genetics; Financial Interests, Institutional, Coordinating PI: Byondis B.V.; Non-Financial Interests, Member: Spanish Society of Medical Oncology (SEOM), American Society for Clinical Oncology (ASCO), Geicam (Spanish Breast Cancer Research Group), European Society for Medical Oncology (ESMO), Sinology Society of the Official College of Physicians of Barcelona (COMB); Non-Financial Interests, Member, Junta Directiva y Comité Científico: SOLTI group (Academic research group in breast cancer). M. Bellet Ezquerra: Financial Interests, Personal, Advisory Board: Pfizer, Novartis, Lilly, Stemline-Menarini; Other, Speaker's Bureau and Travel Expenses: Pfizer; Other, Speaker's Bureau: Novartis, Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
1277P - HRD status of patients with early stage non-small cell lung cancer
Presenter: Apostolos Klinakis
Session: Poster session 04
1278P - ORIGEN: Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain
Presenter: Ernest Nadal
Session: Poster session 04
1279P - Prevalence of EGFR mutations (EGFRm) in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR LATAM
Presenter: Edgar Amorin
Session: Poster session 04
1280P - Comprehensive characterization of human lung squamous cell carcinoma identifies high TFRC expression as a mark of poorly immunogenic tumours
Presenter: María Gutiérrez Pérez
Session: Poster session 04
1281P - Effect of Fra-2 expression on tumour immunogenicity and prognosis in KRAS-mutant lung adenocarcinoma
Presenter: Alvaro Ucero
Session: Poster session 04
1282P - Concordance of PD-L1 expression between biopsy and matched surgical specimen in early-stage non-small cell lung cancer: LC-SCRUM-Advantage/MRD
Presenter: Yoshitaka Zenke
Session: Poster session 04
1283P - Predicting PD-L1 expression using [18F]FDG PET/CT in early stage non-small cell lung cancer (NSCLC)
Presenter: Daniel Hughes
Session: Poster session 04
1284P - Lung cancer among patients with chronic obstructive pulmonary disease: A Danish 10-year observational study of the overlapping population
Presenter: Margrethe Henriksen
Session: Poster session 04
1285P - Lung cancer in never smokers (LCINS): Clinicopathological characteristics and treatment outcomes from a university cancer centre in London
Presenter: Charalampos Gousis
Session: Poster session 04
1287P - Comparing the cost-effectiveness of perioperative immunotherapy strategies in non-small cell lung cancer
Presenter: Bharathi Muthusamy
Session: Poster session 04